Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis

Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study

(2022) Pascal Benkert et al.   LANCET NEUROLOGY

Failed remyelination of the nonhuman primate optic nerve leads to axon degeneration, retinal damages, and visual dysfunction

(2022) Nadège Sarrazin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Long-term Effect of Permanent Demyelination on Axonal Survival in Multiple Sclerosis

(2022) Alexandr Klistorner et al.   Neurology-Neuroimmunology & Neuroinflammation

Imaging correlates of visual function in multiple sclerosis

(2020) Eduardo Caverzasi et al.   PLoS One

A Contrast-Adaptive Methodfor Simultaneous Whole-Brain and Lesion Segmentation in Multiple Sclerosis

(2020) Stefano Cerri et al.   NEUROIMAGE

Longitudinal Serum Neurofilament Levels of Multiple Sclerosis Patients Before and After Treatment with First-Line Immunomodulatory Therapies

(2020) André Huss et al.   Biomedicines

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

(2019) Jens Kuhle et al.   NEUROLOGY

Selective Estrogen Receptor Modulators Enhance CNS Remyelination Independent of Estrogen Receptors

(2019) Kelsey A. Rankin et al.   JOURNAL OF NEUROSCIENCE

Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years

(2019) Ester Cantó et al.   JAMA Neurology

Neurofilament light levels are associated with long-term outcomes in multiple sclerosis

(2019) Jens Kuhle et al.   Multiple Sclerosis Journal

Neurofilaments as biomarkers in neurological disorders

(2018) Michael Khalil et al.   Nature Reviews Neurology

Serum GFAP as a biomarker for disease severity in multiple sclerosis

(2018) A. Abdelhak et al.   Scientific Reports

Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial

(2017) Ari J Green et al.   LANCET

Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery

(2016) Feng Mei et al.   eLife

Pathological mechanisms in progressive multiple sclerosis

(2015) Don H Mahad et al.   LANCET NEUROLOGY

Mechanisms of white matter damage in multiple sclerosis

(2014) Hans Lassmann   GLIA

Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis

(2014) Savina Apolloni et al.   MOLECULAR NEUROBIOLOGY

Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis

(2014) Feng Mei et al.   NATURE MEDICINE

Progressive multiple sclerosis: pathology and pathogenesis

(2012) Hans Lassmann et al.   Nature Reviews Neurology

Glial Progenitor Cell-Based Treatment and Modeling of Neurological Disease

(2012) S. A. Goldman et al.   SCIENCE

The changing demographic pattern of multiple sclerosis epidemiology

(2010) Nils Koch-Henriksen et al.   LANCET NEUROLOGY

Remyelination protects axons from demyelination-associated axon degeneration

(2008) K. A. Irvine et al.   BRAIN